Matching articles for "Segluromet"

Drugs for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • November 14, 2022;  (Issue 1663)
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of...
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-84 | Show Full IntroductionHide Full Introduction

Comparison Chart: SGLT2 Inhibitors (online only)

   
The Medical Letter on Drugs and Therapeutics • November 16, 2020;  (Issue 1611)
...
View the Comparison Chart: SGLT2 Inhibitors
Med Lett Drugs Ther. 2020 Nov 16;62(1611):e184-8 | Show Full IntroductionHide Full Introduction

Drugs for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • November 4, 2019;  (Issue 1584)
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of...
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular complications and death is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease (CVD), a history of severe hypoglycemia, diabetes-related complications, a limited life expectancy, or a long duration of disease.
Med Lett Drugs Ther. 2019 Nov 4;61(1584):169-78 | Show Full IntroductionHide Full Introduction

Ertugliflozin for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • April 23, 2018;  (Issue 1545)
The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with...
The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with metformin (Segluromet) and sitagliptin (Steglujan). Ertugliflozin is the fourth SGLT2 inhibitor to be approved in the US. All four are available in combination with metformin and three are available in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor (see Table 3).
Med Lett Drugs Ther. 2018 Apr 23;60(1545):70-2 | Show Full IntroductionHide Full Introduction